An innovative path to new colorectal cancer treatments

EORTC has connected over 25 leading clinical centers across Europe to set-up the first pan-European Biomarker Screening Platform dedicated to patients with advanced colorectal cancer (CRC).

By screening patients for biomarkers relevant to targeted clinical trials, SPECTAcolor increases the opportunities for CRC patients to access clinical trials with new molecularly defined approaches and simultaneously decreases the cost and logistical pressure of setting up new trials.

  • Pan-European network of top level recruiting clinical centers
  • Exhaustive molecular characterization of CRC patients
  • Certified labs for diagnostic assays
  • Translational research-based clinical trials


Mathilde Fenoulhet
Phone : +32 2 774 15 17

SPECTAcolor is a trademark of the EORTC.
All rights reserved.

Visit the SPECTAcolor blog